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Abstract In the present study, we demonstrated that low,
ineffective doses of N-methyl-D-aspartic acid (NMDA)
receptor antagonists [competitive NMDA antagonist, CGP
37849, at 0.312 mg/kg intraperitoneally (i.p.), antagonist of
the glycineB sites, L-701,324, at 2 mg/kg i.p., partial ago-
nist of glycineB sites, D-cycloserine, at 2.5 mg/kg i.p.]
administered jointly with an ineffective dose of the ben-
zodiazepine, chlordiazepoxide (CDP, 2.5 mg/kg i.p.), sig-
nificantly increased the percentage of time spent in the
open arms of the elevated plus-maze (index of anxiolytic
effect). Furthermore, CDP-induced anxiolytic-like activity
(5 mg/kg i.p.) was antagonized by NMDA (75 mg/kg i.p.)
and by an agonist of glycineB sites of the NMDA receptor
complex, D-serine [100 nmol/mouse intracerebroven-
tricularly (i.c.v.)]. The present study showed a positive
interaction between c-aminobutyric acid (GABA) and
glutamate neurotransmission in the anxiolytic-like activity
in the elevated plus-maze test in mice and this activity
seems to particularly involve the NMDA receptors.
Keywords Chlordiazepoxide  NMDA receptor ligands 
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Introduction
c-Aminobutyric acid (GABA) is the principal inhibitory
neurotransmitter in the mammalian central nervous system
(Sieghart 1995; Sieghart et al. 1999). Dysfunction of the
central GABA system has long been associated with anx-
iety spectrum disorders (Nutt and Malizia 2001; Lydiard
2003; Nemeroff 2003). It is known that in both, humans
and animals, positive modulators of GABAA ionotropic
receptors produce anxiolytic-like activity, while the nega-
tive modulators evoke anxiety (Kalueff and Nutt 1996;
Nutt and Malizia 2001). Thus, for many years, the leading
treatment of anxiety disorders was benzodiazepines that
enhance GABAergic inhibitory neurotransmission through
allosteric modulation of GABAA receptors. They are still
preferred due to their efficacy, rapid onset of action, and
safety (Stahl 2002), but their adverse effects: sedation,
cognitive impairments, undesirable interactions with other
drugs, drug dependence and abuse mostly limited their use
(Uhlenhuth et al. 1999; Stahl 2002). Moreover, these
treatments are effective only in about 70% of patients and
full remission is observed only in 40% of patients; thus, the
novel therapeutic strategies are extensively sought.
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Glutamate, which is the chief excitatory neurotransmitter
in the mammalian central nervous system, is widely dis-
tributed throughout the brain and mediates its effects via
stimulation of ionotropic and metabotropic receptors (Kew
and Kemp 2005). The ionotropic glutamate receptor
family is ligand-gated channels divided into three groups
named after their selective agonists [N-methyl-D-aspartate
(NMDA), a-amino-3-hydroxyl-5-methyl-4-isoxazole-pro-
pionate (AMPA), and kainate] and their density is high in
cortical and limbic regions being implicated in the mediation
of fear and anxiety (Krystal et al. 1999). The preclinical data
indicate that a number of different classes of NMDA receptor
antagonists, acting at specific sites located on the NMDA
receptor complex, produced anxiolytic-like activity in tests
of anxiety in rodents (Dunn et al. 1989; Sharma and Kulkarni
1993; Płaz´nik et al. 1994; Karcz-Kubicha et al. 1997;
Kotlin´ska and Liljequist 1998; Przegalin´ski et al. 2000;
Poleszak et al. 2004). In humans, memantine and D-cyclo-
serine are effective in obsessive–compulsive disorder
(Feusner et al. 2009; Abramowitz et al. 2009; Aboujaoude
et al. 2009), and moreover, D-cycloserine was effective in
post-traumatic stress disorder (Amiel and Mathew 2007).
Despite these findings, the numerous adverse effects produced
by competitive and non-competitive NMDA antagonist
limited their potential clinical use (Tricklebank et al. 1989;
Willetts et al. 1990). Profound side effects, typical for com-
petitive and non-competitive NMDA receptor antagonist, do
not occur after administration glycineB site modulators
(Parsons et al. 1998). This modulatory site of the NMDA
receptor complex is a co-agonist site with affinity for glycine
and D-serine (Wood et al. 1989, 1996). Antagonists and partial
agonist of glycineB sites inhibit the function of the NMDA
receptor complex and produce effects which are similar to
those produced by competitive and non-competitive NMDA
receptor antagonist. It was shown that glycine potentiated the
action of glutamate at NMDA receptors (Johnson and Ascher
1987), and antagonists and partial agonist of the glycineB sites
inhibited the function of the NMDA receptor complex and
produced anxiolytic-like action in several experimental
models of anxiety (Karcz-Kubicha et al. 1997; Przegalin´ski
et al. 1998; Kotlin´ska and Liljequist 1998).
In this study, we investigated the interaction between
glycineB sites ligands and benzodiazepine/GABAA recep-
tor ligand, chlordiazepoxide (CDP) in the elevated plus-
maze test in mice.
Materials and methods
Animals
The experiments were carried out on adult male Albino
Swiss mice (25–30 g) purchased from the licensed breeder
(Kołacz, Warsaw, Poland). The animals were kept in cages
(up to 10 per cage) on a natural day–night cycle with free
access to food and water and they were used after at least
7 days of acclimatization to laboratory conditions. Each
experimental group consisted of 8–12 animals. The
experimental protocol was approved by the Local Ethics
Committee at the Medical University of Lublin (license no.
31/2007), and all the procedures were in strict compliance
with the European Communities Council Directive of 24
November 1986 (86/609/EEC).
Drug administration
Chlordiazepoxide (CDP, Polfa-Poznan´, Poland) was
administered intraperitoneally (i.p.) 60 min before the test.
L-701,324 (7-chloro-4-hydroxy-3-(3- phenoxy)phenyl-
quinolin-2[1H]-one, Sigma) was suspended in a 1% aque-
ous solution of Tween 80 (POCH, Gliwice, Poland) and
administered intraperitoneally (i.p.) 60 min before the test.
NMDA (Sigma), CGP 37849 (DL-(E)-2-amino-4-methyl-5-
phosphono-3-pentenoic acid, Tocris), D-cycloserine (D-4-
amino-3-isoxazolidone, Sigma) were dissolved in 0.9%
NaCl and administered i.p. and also administered 60 min
before the test. D-Serine (Sigma) was also dissolved in
0.9% NaCl and administered intracerebroventricularly
(i.c.v.) 15 min before the test. I.c.v. administration was
performed according to a modified method described by
Lipman and Spencer (1980). Control animals received an
i.p. or i.c.v. injection of a respective vehicle. The volume
of vehicles or drug solutions for i.p. and i.c.v. administra-
tions was 10 ml/kg and 5 ll per mouse, respectively.
Elevated plus-maze test
The experiments were carried out on mice according to the
method of Lister (1987). The plus-maze apparatus was
made of black polyvinyl chloride and consisted of two
open (30 9 5 cm) and two enclosed (30 9 5 9 15 cm)
arms. The arms extended from a central platform of
5 9 5 cm. The apparatus was mounted on a stable base
raising it 38 cm above the floor and was illuminated by red
light. The test consisted of placing a mouse in the center of
the apparatus (facing an enclosed arm) and allowing it to
freely explore the maze. The number of entries into the
open arms and the time spent in these arms were scored for
a 5-min test period. An entry was defined as placing all
four paws within the boundaries of the arm. The following
measures were obtained from the test: the total number of
arm entries, the percentage of entries into the open arms,
the time spent in the open arms expressed as a percentage
of the time spent in both the open and closed arms. Anx-
iolytic activity was indicated by increases in time spent in
open arms or in a greater number of open arm entries. Total
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number of entries into either type of an arm was used as a
measure of the overall motor activity.
Statistical analysis
The obtained data were evaluated by two-way analysis of
variance (ANOVA) followed by Bonferroni’s post hoc test.
All results are presented as a mean ± standard error of the
mean (SEM). A p B 0.05 was considered statistically
significant.
Results
Anxiolytic-like effect of joint administration of CDP
and CGP 37849 in the elevated plus-maze test
Chlordiazepoxide administered at a dose of 0.5 mg/kg or
CGP 37849 administered at a dose of 0.312 mg/kg, both
given alone, did not change the percentage of the time
spent and also entries into the open arms with the exception
of CDP, which significantly increased this latter measure
(Fig. 1). The joint administration of CDP and CGP 37849
significantly increased the percentage of the time spent in
the open arms (Fig. 1a) and enhanced the number of entries
into open arms (Fig. 1b). A two-way ANOVA demon-
strated lack of effect of CDP [F(1, 28) = 1.91,
p = 0.1777], significant effect of CGP 37849 [F(1, 28) =
26.38, p \ 0.0001] and significant interaction [F(1, 28) =
8.02, p = 0.0085] in the time spent in open arms, while a
significant effect of CDP [F(1, 28) = 15.301, p = 0.0005],
no effect of CGP 37849 [F(1, 28) = 2.93, p = 0.09882]
and no interaction [F(1, 28) = 0.0, p = 0.9492] in the
open arm entries.
Anxiolytic-like effect of joint administration of CDP
and L-701,324 in the elevated plus-maze test
Chlordiazepoxide administered at a dose of 0.5 mg/kg did
not alter the percentage of time spent and increased entries
into the open arms (Fig. 2). L-701,324 given alone at a
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Fig. 1 Effect of joint administration of CGP 37849 and chlordiaz-
epoxide (CDP) in the elevated plus-maze procedure in mice [the
percentage of the time spent in the open arms (a), and the percentage
of the open arms entries (b)]. CGP 37849 and CDP was administered
i.p. 60 min before the test. The values represent the mean ± SEM
(n = 8 mice per group) *p \ 0.05 versus CGP 37849, ^p \ 0.001
versus CDP, #p \ 0.05 versus control (vehicle-treated group)
(Bonferroni’s test)
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Fig. 2 Effect of joint administration of L-701,324 and chlordiaz-
epoxide (CDP) in the elevated plus-maze procedure in mice [the
percentage of the time spent in the open arms (a), and the percentage
of the open arms entries (b)]. L-701,324 and CDP was administered
i.p. 60 min before the test. The values represent the mean ± SEM
(n = 8 mice per group) *p \ 0.01 versus L-701,324, ^p \ 0.01 versus
CDP, #p \ 0.01 versus control (vehicle-treated group) (Bonferroni’s
test)
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dose of 2 mg/kg exhibited no effect in this test (Fig. 2a, b).
The joint administration of CDP and L-701,324 (both in
ineffective per se doses) significantly increased the per-
centage of time spent in the open arms (Fig. 2a), but not in
the number of entries into open arms (Fig. 2b). A two-way
ANOVA demonstrated a significant effect of CDP [F(1,
28) = 7.66, p = 0.0099], a significant effect of L-701,324
[F(1, 28) = 9.65, p \ 0.0043] and not quite significant
interaction [F(1, 28) = 3.83, p = 0.0603] in the time spent
in open arms, while a significant effect of CDP [F(1, 28) =
7.25, p = 0.0118], no effect of L-701,324 [F(1, 28) =
1.09, p = 0.3056] and not quite significant interaction
[F(1, 28) = 3.77, p = 0.0622] in the open arm entries.
Anxiolytic-like effect of joint administration of CDP
and D-cycloserine in the elevated plus-maze test
Chlordiazepoxide administered at a dose of 0.5 mg/kg
did not change either the percentage of the time spent
(Fig. 3a) or the number of entries into open arms (Fig. 3b).
D-Cycloserine administered singly at a dose of 2.5 mg/kg
remained also without any effect on both of these measures
(Fig. 3a, b). CDP administered at an ineffective per se dose
of 0.5 mg/kg and D-cycloserine administered at such a dose
of 2.5 mg/kg significantly increased the percentage of the
time spent in the open arms (Fig. 3a) and enhanced the
number of entries into open arms (Fig. 3b). A two-way
ANOVA demonstrated a significant effect of CDP
[F(1, 34) = 24.83, p \ 0.0001], a significant effect of DCS
[F(1, 34) = 8.73, p = 0.0057] and a significant interaction
[F(1, 34) = 13.35, p = 0.0009] in the time spent in the
open arms, while a significant effect of CDP
[F(1, 34) = 19.50, p \ 0.0001], a significant effect of DCS
[F(1, 34) = 4.31, p = 0.0451] and no interaction
[F(1, 34) = 2.93, p = 0.0956] in the open arm entries.
Effect of NMDA on the anxiolytic-like activity
of CDP in the elevated plus-maze test
Chlordiazepoxide given at a dose of 2 mg/kg produced
anxiolytic-like effect significantly increasing the percent-
age of the time spent in the open arms and increasing the
percentage of the entries into the open arms (Fig. 4). The
increase in percentage of the time spent in the open arms
induced by CDP (2 mg/kg) was significantly reversed by
NMDA (75 mg/kg) (Fig. 4a). The increase in the number
of the open arm entries induced by CDP (2 mg/kg) was
significantly decreased by NMDA (Fig. 4b). NMDA given
alone had no effect on either the time spent or the entries
into the open arms (Fig. 4). A two-way ANOVA demon-
strated a significant effect of CDP [F(1, 36) = 45.98,
p \ 0.0001], a significant effect of NMDA [F(1, 36) =
21.37, p \ 0.0001] and a significant interaction [F(1,
36) = 21.19, p \ 0.0001] in the time spent in open arms,
and a similarly significant effect of CDP [F(1, 36 = 15.87,
p = 0.0003], a significant effect of NMDA [F(1, 36) =
8.11, p = 0.0072] and a significant interaction [F(1, 36) =
11.91, p = 0.0014] in the open arm entries.
Effect of D-serine on the anxiolytic-like activity of CDP
in the elevated plus-maze test
Chlordiazepoxide given at a dose of 2 mg/kg produced an
anxiolytic-like effect significantly increasing the percent-
age of the time spent in the open arms and increasing the
percentage of the entries into the open arms (Fig. 5). The
increase in the percentage of the time spent in the open
arms induced by CDP (2 mg/kg) was significantly reversed
by D-serine (100 nmol/mouse) (Fig. 5a). The increase in
the number of the open arm entries induced by CDP (2 mg/kg)
was significantly changed by D-serine (Fig. 5b). D-Serine
given alone had no effect on either the time spent or the
entries into the open arms (Fig. 5). A two-way ANOVA
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Fig. 3 Effect of joint administration of D-cycloserine (DCS) and
chlordiazepoxide (CDP) in the elevated plus-maze procedure in mice
[the percentage of the time spent in the open arms (a), and the
percentage of the open arms entries (b)]. L-701,324 and CDP was
administered i.p. 60 min before the test. The values represent the
mean ± SEM (n = 9–10 mice per group) *p \ 0.001 versus DCS,
^p \ 0.05, ^^p \ 0.001 versus CDP (Bonferroni’s test)
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demonstrated a significant effect of CDP [F(1, 33) = 23.80,
p \ 0.0001], a significant effect of D-serine [F(1, 33) =
18.49, p = 0.0001] and a significant interaction [F(1, 33) =
16.33, p \ 0.0003] in the time spent in the open arms, while a
significant effect of CDP [F(1, 33) = 4.97, p = 0.0321], no
effect of D-serine [F(1, 33) = 2.93, p = 0.0957] and a sig-
nificant interaction [F(1, 33) = 9.11, p = 0.0046] in the
open arm entries.
Effect of CDP and NMDA ligands on the
total arm entries
Chlordiazepoxide and all tested NMDA receptor ligands,
administered singly or in combination, did not alter the
number of the total arm entries (Table 1). A two-way
ANOVA demonstrated the lack of the significant inter-
action between treatments in all analyzed experiments A:
F(1, 28) = 0.74, p = 0.3964, B: F(1, 28) = 0.53, p =
0.4723], C: F(1, 36) = 3.25, p = 0.0797, D: F(1, 36) =
2.59, p = 0.1164, E: F(1, 36) = 1.02, p = 0.3185.
Discussion
A number of behavioral data have suggested the involve-
ment of the glutamate-mediated neurotransmission in an
anxiolytic-like behavior. The anxiolytic-like activity was
demonstrated for different modulatory sites of NMDA
receptor complex: for a non-competitive NMDA antago-
nist, dizocilpine (MK-801) (Dunn et al. 1989; Sharma and
Kulkarni 1993; Karcz-Kubicha et al. 1997), a competitive
NMDA antagonist, 2-amino-7-phosphoheptanoic acid
(AP7) (Płaz´nik et al. 1994), CGP 37849 (Przegalin´ski et al.
2000), and partial agonists of glycineB sites, D-cycloserine
(Karcz-Kubicha et al. 1997) and 1-aminocyclo-propane-
carboxylic acid (ACPC) (Trullas et al. 1989; Trullas et al.
1991), and antagonist of glycineB sites: L-701,324 (Karcz-
Kubicha et al. 1997; Przegalin´ski et al. 1998; Kotlin´ska and
Liljequist 1998). The anxiolytic-like profile of different
NMDA antagonists was similar to that of benzodiazepines
(Płaz´nik et al. 1994) and the excitatory amino acid agonist,
NMDA, produced anxiogenic-like effects in the elevated
plus-maze test (Dunn et al. 1989). Moreover, genetic
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Fig. 4 Effect of N-methyl-D-aspartate (NMDA) on the action of
chlordiazepoxide (CDP) in the elevated plus-maze procedure in mice
[the percentage of the time spent in the open arms (a) and the
percentage of the open arms entries (b)]. NMDA and CDP was
administered i.p. 60 min before the test. The values represent the
mean ± SEM (n = 10 mice per group) *p \ 0.001 versus CDP,
#p \ 0.001, versus control (vehicle-treated group) (Bonferroni’s test)
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Fig. 5 Effect of D-serine (DS) on the action of chlordiazepoxide
(CDP) in the elevated plus-maze procedure in mice [the percentage of
the time spent in the open arms (a), and the percentage of the open
arms entries (b)]. CDP was administered i.p. 60 min before the test,
DS was administered i.c.v. 45 min after CDP injection. The values
represent the mean ± SEM (n = 9–10 mice per group) *p \ 0.01,
**p \ 0.001 versus CDP, #p \ 0.01, ##p \ 0.001, versus control
(vehicle-treated group) (Bonferroni’s test)
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studies indicated an anxiolytic-like activity of NR2A sub-
unit of NMDA receptor knockout mice (Boyce-Rustay and
Holmes 2006). Validation of the elevated plus-maze pro-
cedure has shown that it is sensitive to drugs that produce
anxiolytic or anxiogenic effects in human (Pellow et al.
1985), including drugs that have non-benzodiazepine sites
of action (Pellow 1986). Moreover, in the clinical study
showed useful of memantine (non-competitive NMDA
receptor antagonist) augmentation in treatment-resistant
obsessive–compulsive disorder (Feusner et al. 2009;
Aboujaoude et al. 2009), D-cycloserine (partial agonists of
glycineB sites) (Hood et al. 1989; Emmett et al. 1991) as a
potential therapeutic agent for post-traumatic stress disor-
der and specific phobia (Heresco-Levy et al. 2002; Ressler
et al. 2004), and riluzole in the treatment of symptoms
obsessive–compulsive disorder (Coric et al. 2005) and
general anxiety disorder (Mathew et al. 2005).
In the present study, we have demonstrated the influence
of NMDA receptor ligands on anxiolytic-like activity of
CDP in the elevated plus-maze in mice. We have shown
that a competitive NMDA antagonist (CGP 37849), partial
agonist of the glycineB site (D-cycloserine) and glycineB
antagonist (L-701,324) enhanced the anxiolytic-like activ-
ity of CDP in the elevated plus-maze. The previous study
has shown that CGP 37849 evoked potentially anxiolytic-
like effects in the Vogel conflict drinking test, an open field
test (Płaz´nik et al. 1994) and in the elevated plus-maze test
in rats and its anxiolytic-like activity was abolished by
flumazenil (Przegalin´ski et al. 2000). In our study,
0.312 mg/kg CGP 37849 produced synergistic effects with
CDP (0.5 mg/kg) in the elevated plus-maze test in mice.
Unfortunately, the side effects produced by competitive
and uncompetitive NMDA antagonist (motor impairment,
hyperactivity, stereotypy and psychotomimetic actions
(Willetts et al. 1990) limited their potential use for the
treatment in humans. After the discovery that the NMDA
receptor activity is regulated by co-agonist (glycine or
D-serine), numerous studies concentrated on this pathway.
It is known that a co-agonist site exerts major regulatory
roles in the activity of NMDA receptor complex. The
binding of the co-agonist (glycine or D-serine) is an
obligatory requirement for NMDA receptor/channel activ-
ity (Johnson and Ascher 1987; Kleckner and Dingledine
1988). More recently, studies have shown that selective
blockers of the co-agonist site abolish NMDA receptor
activity (Kessler et al. 1989; Kleckner and Dingledine
1989) and produced pharmacological effects similar to
those exerted after the administration of a competitive and
non-competitive NMDA antagonist. D-Cycloserine has a
profile of a partial agonist acting at the glycine binding site
(Hood et al. 1989; Watson et al. 1990). In the preclinical
data D-cycloserine exhibits anxiolytic-like effects in the
Vogel conflict test (Kłodzin´ska and Chojnacka-Wo´jcik
2000), in the elevated plus-maze (time in open arms)
(Karcz-Kubicha et al. 1997; Ho et al. 2005; Poleszak et al.
2008), and in a fear-potentiated startle response test
(Anthony and Nevins 1993) (Campeau et al. 1992; Fendt
et al. 1996). The glycineB receptor antagonist (L-701,324)
has produced anxiolytic-like effects in the elevated plus-
maze test and the four-plate test (Karcz-Kubicha et al. 1997;
Przegalin´ski et al. 1998; Kotlin´ska and Liljequist 1998).
In our study, the combined treatment with CDP and
L-701,324 (a glycineB site antagonist) or D-cycloserine (a
glycine site partial agonist), all at low, ineffective doses,
increased the time spent in the open arms of the elevated
plus-maze, with no effects on the number of total entries
(Table 1). Because the obtained data indicate a lack of
effect on the locomotor activity, we can assume that this
combination produced an anxiolytic-like activity. The
Table 1 The number of the total arm entries for all experimental
groups
Treatment and dose Number of total entries
A
Vehicle 12.63 ± 0.46
CDP 0.5 mg/kg 12.00 ± 1.00
CGP 37849 0.312 mg/kg 13.25 ± 1.21
CDP 0.5 mg/kg and CGP 37849 0.312 mg/kg 14.75 ± 1.85
B
Vehicle 14.38 ± 1.75
CDP 0.5 mg/kg 15.75 ± 1.46
L-701,324 2 mg/kg 13.50 ± 1.04
CDP 0.5 mg/kg and L-701,324 mg/kg 16.75 ± 0.59
C
Vehicle 14.50 ± 0.74
CDP 0.5 mg/kg 11.44 ± 0.67
D-cycloserine 2.5 mg/kg 12.80 ± 0.70
CDP 0.5 mg/kg and D-cycloserine 2.5 mg/kg 12.00 ± 0.92
D
Vehicle 11.80 ± 1.07
CDP 2 mg/kg 15.30 ± 1.90
NMDA 75 mg/kg 13.20 ± 0.53
CDP 2 mg/kg and NMDA 75 mg/kg 12.80 ± 0.92
E
Vehicle 15.10 ± 1.65
CDP 2 mg/kg 19.30 ± 0.71
D-serine 100 nmol/mouse 12.40 ± 1.33
CDP 2 mg/kg and D-serine 100 nmol/mouse 17.40 ± 1.32
Data represent the mean ± SEM; n = 9–12. Chlordiazepoxide
(CDP), CGP 37849, L-701,324, D-cycloserine and N-methyl-D-
aspartate (NMDA) were administered i.p. 60 min before the test.
D-serine was administered i.c.v. 15 min before the test
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anxiolytic-like activity of CDP was reduced by NMDA or
by D-serine, what suggests the involvement of NMDA
receptor complex in the anxiolytic activity of CDP in the
elevated plus-maze in mice. The interaction between
NMDA and GABAergic neurotransmission in anxiety
assessments in animals was shown in other experiments.
The anxiolytic-like activity of MK-801 was enhanced by
diazepam, antagonized by the benzodiazepine receptor
antagonist (Ro-15-1788) and reversed by the anxiogenic
agent, b-carboline FG-7142 (Sharma and Kulkarni 1993).
To summarize, the present study indicates the involve-
ment of the NMDA receptor complex in the anxiolytic-like
activity of CDP in the EMP in mice. Our results also
suggest that full anxiolysis might be possible with a
reduced dose of benzodiazepines when co-administered
with NMDA receptor antagonists and this might substan-
tially reduce side effects and the risk of the benzodiazepine
dependence. Clinical trials are necessary to determine if
such a combination is of a potentially therapeutic value in
humans with anxiety disorders.
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